ライフサイエンスコーパス: 6-MP

1 6-MP adherence data were available for 63.7% of study pa

2 6-MP ingestion habits examined included: takes 6-MP with

3 6-MP should be part of the initial treatment regimen for

4 6-MP use before or at conception or during pregnancy app

5 6-MP was more effective than placebo ( P < 0.05) at prev

6 6-MP, 50 mg daily, was more effective than placebo at pr

7 proof-of-principle mosaic image shown with 3.6 MP.

8 leukocyte transmigration was inhibited after 6-MP/6-T-GTP treatment.

9 s study was to analyze the safety of AZA and 6-MP and steroid reduction in this age group.

10 AZA and 6-MP were well tolerated in 82% of patients; of these, p

11 d total therapeutic dose of azathioprine and 6-MP.

12 ssociation between 6-MP ingestion habits and 6-MP adherence, red cell thioguanine nucleotide (TGN) le

13 bined administration of clinically available 6-MP to overcome TMZ chemoresistance and improve GBM tre

14 Because 6-MP and its derivative 6-thioguanosine-5'-triphosphate

15 This study examines the association between 6-MP ingestion habits and 6-MP adherence, red cell thiog

16 osticators, there was no association between 6-MP ingestion habits and relapse risk (6-MP with food:

17 s to capture leukocytes, also was reduced by 6-MP/6-T-GTP.

18 the rate of flux of [(3)H]adenine and [(14)C]6-MP across the plasma membrane.

19 [(14)C]6-MP and [(3)H]adenine had K (m) values (+/-S.D.) of 163

20 Certain 6-MP ingestion habits were associated with nonadherence

21 ar incorporation of DNA-TGN for 6-TG but for 6-MP significantly reduced DNA-TGN in TPMT-induced compa

22 ls, and changes in SLC43A3 expression impact 6-MP cytotoxicity.

23 Indeed, 6-MP and 6-T-GTP decreased Rac1 activation in endothelia

24 uanine, and 6-methylmercaptopurine inhibited 6-MP uptake with K (i) values of 1.0 +/- 0.4, 67 +/- 30,

25 led by the ADSS inhibitor 6-mercaptoethanol (6-MP).

26 hough the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well established agen

27 rrent trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of

28 iopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators and cytotoxic agen

29 Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients with ulcerative col

30 ioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppressive drugs.

31 6-Mercaptopurine (6-MP) is a nucleobase analog used in the treatment of ac

32 l experience suggests that 6-mercaptopurine (6-MP) is effective therapy for children with active ster

33 tion, or administration of 6-mercaptopurine (6-MP), a clinically approved inhibitor of HPRT1, blocks

34 uate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485 patients who had r

35 eated with azathioprine or 6-mercaptopurine (6-MP).

36 rs [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (infliximab, adalimumab

37 generally instructed to take mercaptopurine (6-MP) in the evening and without food or dairy products.

38 of continuation therapy with mercaptopurine (6-MP) and asparaginase (L-ASP).

39 high DI phenotype (either 6-mercaptopurine [6-MP] or methotrexate [MTX] DI >=110% during the first 4

40 Moreover, 6-MP and 6-T-GTP selectively decreased TNF-alpha-induced

41 important component of the mode of action of 6-MP is inhibition of purine de novo synthesis (PDNS) th

42 Addition of 6-MP to a regimen of corticosteroids significantly lesse

43 ticenter trial evaluating the combination of 6-MP and prednisone as therapy for children with newly d

44 For equitoxic doses of 6-MP, equivalent levels of MeTIMP correlated with equiva

45 a underscore the anti-inflammatory effect of 6-MP and 6-T-GTP on endothelial cells by blocking Rac1 a

46 ity of the cells to the cytotoxic effects of 6-MP by more than 7-fold.

47 T1 also mediated adenine-sensitive efflux of 6-MP from the SLC43A3-HEK293 cells.

48 MRP4 also contributed to the efflux of 6-MP in this model, but was less efficient than ENBT1 in

49 mechanism underlying the protective role of 6-MP in endothelial cell activation is investigated.

50 of ENBT1 are key players in the transfer of 6-MP into and out of cells, and changes in SLC43A3 expre

51 AZA or 6-MP was tolerated in 51 of 95 patients (54%) without ad

52 reased risk of lymphoma with azathioprine or 6-MP therapy, an increased risk was not observed in this

53 se patients not treated with azathioprine or 6-MP, the relative risk of lymphoma among the 1465 infla

54 ncluded 441 children with ALL receiving oral 6-MP for maintenance.

55 e centers randomized 131 patients to receive 6-MP (50 mg), mesalamine (3 g), or placebo daily in a do

56 77% (95% CI, 61%-91%) in patients receiving 6-MP, mesalamine, and placebo, respectively.

57 Future recommendations regarding 6-MP intake during maintenance therapy for childhood ALL

58 ween 6-MP ingestion habits and relapse risk (6-MP with food: hazard ratio [HR], 0.7; 95% CI, 0.3 to 1

59 Commonly practiced restrictions surrounding 6-MP ingestion might not influence outcome but may hinde

60 analyzed as to whether the patient had taken 6-MP before, or at the time of, conception.

61 6-MP with versus never with dairy, and takes 6-MP in the evening versus morning versus varying times.

62 akes 6-MP with versus never with food, takes 6-MP with versus never with dairy, and takes 6-MP in the

63 MP ingestion habits examined included: takes 6-MP with versus never with food, takes 6-MP with versus

64 ation between red cell TGN levels and taking 6-MP with food versus without (206.1 +/- 107.1 v 220.6 +

65 ents who had their pregnancies before taking 6-MP.

66 women who had taken or were currently taking 6-MP to controls.

67 ts were associated with nonadherence (taking 6-MP with dairy [odds ratio (OR), 1.9; 95% CI, 1.3 to 2.

68 ections among male or female patients taking 6-MP compared with controls (RR = 0.85 [0.47-1.55], P =

69 We hypothesized that 6-MP is a substrate for both variants of ENBT1.

70 both groups, only 9% of the remitters in the 6-MP group relapsed compared with 47% of controls (P = 0

71 In the 6-MP group, the duration of steroid use was shorter (P<0

72 aminotransferase activity were noted in the 6-MP group.

73 trated a 4.4-fold increase in sensitivity to 6-MP.

74 cytotoxic potential in patients treated with 6-MP, because different levels of DNA-TGN may be associa

75 /-2 years) were randomized to treatment with 6-MP (1.5 mg x kg(-1) x day(-1)) or placebo within 8 wee

76 Study treatment with 6-MP or placebo continued for 18 months.